Deoxycoformycin in the treatment of patients with hairy cell leukemia

Rafel, Montserrat; Cervantes, Francisco; Beltrán, José María García; J., Zuazu, Francisco; Nieto, Luis Hernández; Rayón, Consuelo; Talavera, Juan García; Montserrat, Emilio

doi:10.1002/(sici)1097-0142(20000115)88:2<352::aid-cncr15>3.0.co;2-8

Cited by 59 publications

(32 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most instances the prognosis of patients with HCL is good, with an overall survival of around 85% at 8 years from diagnosis. [2][3][4] Hairy cells strongly express CD20, CD22 and monoclonal surface immunoglobulins, together with the distinctive expression of CD25, CD11c, FMC7 and CD103. Trisomy 5, structural abnormalities involving the pericentromeric regions of chromosomes 5 and 2, 1q42 abnormalities, and 14q alterations are frequently found in patients with HCL, 5 but there is no recurrent chromosomal aberration typical of this disease.…”

Section: Introductionsupporting

confidence: 66%

Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?

et al. 2002

View full text Add to dashboard Cite

The association of hairy cell leukemia (HCL) with other neoplasms, mainly non-Hodgkin's lymphomas, is well known. However, the simultaneous diagnosis of HCL and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is rare, with only few cases of such an association having been reported. We describe three patients with a well-characterized HCL in whom a CLL/SLL population was detected. Of note, these cases represent a significant proportion (11.5%; 95% CI: 0% to 24%) of the total number of HCL cases diagnosed in our institution during the same period of time. All three patients were treated with deoxycoformycin. They achieved a complete response of the HCL, whereas the CLL/SLL population persisted in all cases. The immunoglobulin gene rearrangement analysis, in two informative cases, suggested that the HCL and CLL/SLL populations arose from different B cell clones. This study indicates that the association of HCL and CLL/SLL might be much more frequent than previously recognized. Therefore, a large panel of monoclonal antibodies, including those necessary to detect CLL/SLL, should be employed when studying patients with HCL.

show abstract

Section: Introductionsupporting

confidence: 66%

Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?

et al. 2002

View full text Add to dashboard Cite

show abstract

“…5,6 Treatment with 2-chlorodeoxyadenosine or 2 0 -deoxycoformycin resulted in 80% to 90% CR, with a relapse rate of 25% to 30% at 3-to 5-year follow-up. 7 In past years, several reports [8][9][10][11][12][13][14] of long-term follow-up studies with a single purine analogue have confirmed that the overall CR rates are very similar, ranging from 76% to 98%, and the relapse rates are equally comparable, showing that about 30% to 40% of patients would relapse after 5 to 10 years of follow-up. These reports indicate that both purine analogues are highly effective and lead to excellent overall survival; however, it appears that neither purine analogue is likely curative, because molecular studies suggest that all patients have evidence of minimal residual disease while in CR.…”

mentioning

confidence: 96%

Hairy cell leukemia

Zinzani

Pellegrini

Stefoni

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alphainterferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients. METHODS: The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n ¼ 53) were treated with 2 lines, Group C patients (n ¼ 34) with 3 lines, Group D patients (n ¼ 17) with 4 lines, and Group E patients (n ¼ 8) with 5 lines. RESULTS: In Group A, 92 (77%) patients obtained a complete response (CR), 23 (18%) a partial response, and the remaining 6 (5%) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5%; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5% (median duration of response, 2.2 years). In Group D, 11 (64.7%) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50%) of 8 patients achieved a CR (median duration of response, 1.3 years). CONCLUSIONS: This study confirms the high risk (>40% of all patients) of retreatment of HCL patients and the need to maximize primary response. Cancer 2010;116:4788-92.

show abstract

“…A number of reports including large number of patients treated with one of these two purine analogues have documented an overall response rate (ORR) of 95% with greater than 85% of patients achieving a CR [35][36][37][38][39][40][41]. Therefore at present, either purine analogue is considered the first line treatment in HCL.…”

Section: Treatmentmentioning

confidence: 99%

Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias

Matutes¹

2012

CCDT

View full text Add to dashboard Cite

Rarer chronic lymphoid leukaemias represent a challenge to the clinicians due to the limited information on their pathogenesis, difficulties on setting up prospective clinical trials and to their refractoriness to drugs used in the most common form of chronic lymphocytic leukaemia (CLL). In this review all these issues are addressed in three B-cell leukaemias: B-cell prolymphocytic leukaemia (B-PLL), hairy cell leukaemia (HCL) and HCL-variant and three T-cell leukaemias: T-cell prolymphocytic leukaemia (T-PLL), T-cell large granular lymphocytic leukaemia (T-cell LGLL) and adult T-cell leukaemia lymphoma (ATLL). Data will be presented on the natural history, current therapies and emerging drugs potentially useful in the treatment of patients with these leukaemias. Emphasis is made on: 1- the novel agents targeting a variety of B and T-cell antigens expressed on the surface of the leukaemic cells; these are either unconjugated monoclonal antibodies (McAb) such as Rituximab (anti-CD20), the second and third generation of anti-CD20 McAbs, Alemtuzumab (anti-CD52), Siplizumab (anti-CD2), Daclizumab (anti-CD25) and KW-0761, an anti-chemokine receptor 4 (CCR4) or McAbs conjugated to toxins such as CD22 linked to the pseudomonas exotoxin or radiolabelled McAb; 2- the use of new purine nucleosides such as nelarabine and 3- agents targeting deregulated genes in the leukaemic cells from these diseases such as the Poly (ADP-ribose) polymerase (PARP) Olarapib in T-PLL with deregulation of the ataxia telangiectasia mutated (ATM) gene. Data of phase I and II clinical studies with these agents as well as the potential and current use of other drugs are outlined.

show abstract

Deoxycoformycin in the treatment of patients with hairy cell leukemia

Cited by 59 publications

References 24 publications

Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?

Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?

Hairy cell leukemia

Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias

Contact Info

Product

Resources

About